Who Paid My Doc
James McCarty
Pediatric Infectious Diseases Madera, CA Medical Doctor
NPI 1598777500 CMS profile 522346
9300 Valley Childrens Pl, Apt 202, Madera, CA 93638
General payments
$877,182
Research payments
$910,679
Ownership & investment interest
$0
Through program year 2025, James McCarty of Madera, CA is reported in the CMS Open Payments database as having received $877,182 across 257 general payments and $910,679 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $47,122 | 11 | |
| 2025 | Research | $160,641 | 17 | |
| 2024 | General | $955 | 1 | |
| 2024 | Research | $102,988 | 19 | |
| 2023 | General | $203,334 | 50 | |
| 2023 | Research | $125,650 | 23 | |
| 2022 | General | $218,016 | 88 | |
| 2022 | Research | $215,688 | 47 | |
| 2021 | General | $209,888 | 61 | |
| 2021 | Research | $145,763 | 61 | |
| 2020 | General | $155,067 | 35 | |
| 2020 | Research | $159,950 | 50 | |
| 2019 | General | $42,800 | 11 |
Beside peers
- James McCarty
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to James McCarty were reported at $47,122. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | James McCarty | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $42,800 | $175 | $34–$2,175 | $163 |
| 2020 | $155,067 | $521 | $34–$6,009 | $114 |
| 2021 | $209,888 | $1,077 | $39–$4,557 | $132 |
| 2022 | $218,016 | $232 | $53–$6,196 | $149 |
| 2023 | $203,334 | $140 | $52–$4,662 | $160 |
| 2024 | $955 | $198 | $52–$3,860 | $164 |
| 2025 | $47,122 | $126 | $41–$2,094 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
474 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in California
Lashonda Spencer
Pediatric Infectious Diseases · Los Angeles, CA
Antonio Arrieta
Pediatric Infectious Diseases · Orange, CA
John Bradley
Pediatric Infectious Diseases · San Diego, CA
Hayley Gans
Pediatric Infectious Diseases · Palo Alto, CA
Yvonne Maldonado
Pediatric Infectious Diseases · Stanford, CA
Audra Deveikis
Pediatric Infectious Diseases · Long Beach, CA
Related records
Pediatric Infectious Diseases in California
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.